【摘要】 目的:探讨罗格列酮(RGZ)对糖尿病肾病大鼠肾组织结缔组织生长因子(CTGF)表达的影响。方法:大鼠随机分成治疗组、模型组、正常组(n=9)。治疗组、模型组大鼠用链脲佐菌素(STZ)诱导糖尿病肾病模型,均造模成功7只。治疗组大鼠于造模前24h行RGZ灌胃,模型组和正常组以等体积蒸馏水灌胃。12周后处死动物,观察肾小球病理学变化及细胞外基质(ECM)相对面积,用免疫组织化学法检测肾皮质CTGF的表达。结果:治疗组及模型组肾小球ECM相对面积及肾皮质CTGF表达水平均较正常组升高,但治疗组2指标均较模型组低(P<0.01);治疗组肾脏病理学改变较模型组减轻。结论:RGZ能改善糖尿病时肾脏的病理变化,延缓肾纤维化的发生,其作用可能与抑制肾组织中CTGF的表达有关。更多还原

【Abstract】 Aim: To study the effect of rosiglitazone(RGZ) on expression of connective tissue growth factor (CTGF) in renal tissue of diabetic nephropathy rats.Methods: Thirty male Wistar rats were randomly divided into RGZ-treatment group, model group and normal group. Hyperglycemia was induced with streptozotocin in rats of RGZ-treatment group and model group. The glomerular extracellular matrix (ECM) deposition was measured. Nephric pathology changes were observed using HE and PAS staining, respectively. The method of immunohistochemisty was used to evaluate the expression of CTGF in renal tissue. Results:The glomerular ECM deposition in RGZ-treatment group was significantly lower than that of the model group (P<0.01). Nephric pathology study showed that RGZ can improve the pathological states of the renal tissue of diabetic nephropathy rats.The expression of CTGF in RGZ group was markedly reduced compared with the model group (P<0.01). Conclusion: RGZ could ameliorate the pathology changes in nephropathy of the diabetic rats and delay the occurrence of renal fibrosis of the diabetic rats,which may be associated with inhibiting the expression of CTGF in the kidney.更多还原